Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Cristiano Ferrario, Aude Fléchon et al.|The Lancet|2017Cited by 177
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P. Petrylak, Siobhan Ng, Ronald de Wit et al.|The Lancet Oncology|2019Cited by 87
LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE studyNiels Reinmuth, Filippo de Marinis, Mustafa Özgüroğlu et al.|Immuno-Oncology Technology|2023Cited by 2
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)Arlene O. Siefker‐Radtke, Yohann Loriot, Mehmet Asım Bilen et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 0